Becton, Dickinson and Company Prices Offerings Of $2.25 Billion Of Common Stock And $2.25 Billion Of Depositary Shares Representing Interests In Mandatory Convertible Preferred Stock Post author:Sam Post published:May 10, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like FDA Raises Big Safety Concerns With Johnson & Johnson's Arthritis Drug Sirukumab July 30, 2017 2 Biotechs Taking on the $20 Billion Alzheimer's Market Full Force February 12, 2017 Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases October 2, 2017
Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases October 2, 2017